Full text is available at the source.
Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis
Effectiveness, dropout rates, and safety of serotonin-related psychedelics and MDMA for treating mental health conditions
AI simplified
Abstract
30 clinical trials involving 1,480 participants were analyzed for the effects of MDMA and serotonergic psychedelics on mental disorders.
- MDMA significantly reduced PTSD symptoms compared to control groups.
- Psilocybin, ayahuasca, and LSD were linked to reduced depressive symptoms in major depressive disorder.
- Both MDMA and serotonergic psychedelics may lower anxiety symptoms, though the evidence varies.
- Psilocybin and LSD did not improve abstinence rates in alcohol use disorder.
- LSD showed no significant effect on ADHD symptoms.
- Moderate certainty was found for MDMA's effectiveness on PTSD, while the risk of discontinuation was not higher with these treatments.
AI simplified